Medicine and Dentistry
Adriamycin Bleomycin Vinblastine Dacarbazine
14%
Adverse Outcome
17%
Anaplastic Large Cell Lymphoma
52%
Anthracycline
24%
Autologous Stem Cell Transplantation
21%
Biological Marker
30%
Biopsy
27%
Bleomycin
22%
Breast Implant
21%
Cancer
20%
Classical Hodgkin Lymphoma
88%
Clinical Trial
17%
Cohort Analysis
55%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Diagnosis
46%
Diffuse Large B-Cell Lymphoma
86%
Disease
59%
Epstein Barr Virus
44%
Etoposide
17%
Follicular Lymphoma
93%
Hazard Ratio
28%
Hodgkin's Lymphoma
77%
Ibrutinib
21%
Immunohistochemistry
20%
Lymphoma
60%
Maculopapular Rash
23%
Malignant Neoplasm
21%
Multivariate Analysis
22%
Myeloproliferative Neoplasm
21%
Neoplasm
62%
NK T Cell Lymphoma
21%
Non-Hodgkin Lymphoma
18%
Overall Survival
79%
Peripheral T-Cell Lymphoma
98%
Positron Emission Tomography
17%
Positron Emission Tomography-Computed Tomography
52%
Posttransplant Lymphoproliferative Disease
32%
Predictive Marker
21%
Programmed Death 1 Receptor
23%
Progression Free Survival
46%
Proportional Hazards Model
18%
Protein Expression
19%
Proteomics
25%
Quality of Life
16%
Radiation Therapy
16%
Rituximab
54%
Systemic Therapy
16%
T Cell
15%
T-Cell Lymphoma
19%
Tissue Microarray
16%
Immunology and Microbiology
Aleutian Mink Disease Virus
10%
Arm
11%
Autologous Stem Cell Transplantation
10%
Avelumab
10%
B Cell
100%
CD163
10%
CD44
10%
CD8
11%
Cell Death
10%
Cell Population
6%
Cell Survival
10%
Chemosensitivity
10%
Comorbidity
21%
Crohn's Disease
10%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
32%
Death Receptor
10%
Epstein Barr Virus
31%
Epstein Barr Virus
7%
Galectin 1
10%
Gene Expression
8%
Gene Mutation
10%
Hemoglobin Blood Level
10%
Human Leukocyte Antigen
9%
Infliximab
10%
Kidney Transplantation
10%
Leukocyte
10%
Life Expectancy
10%
Lymphocyte
11%
Lymphocyte Count
12%
Lymphoma Cell
22%
Lymphoproliferative Disorders
24%
Molecular Epidemiology
10%
Natural Killer T Cell
10%
Neutrophil
10%
Neutrophil Count
10%
Overall Survival
73%
Peripheral T-Cell Lymphoma Not Otherwise Specified
10%
Positron Emission Tomography
16%
Programmed Death 1 Receptor
24%
Programmed Death-Ligand 1
9%
Progression Free Survival
47%
Protein Expression
18%
Reed Sternberg Cell
8%
Rituximab
54%
Signal Transduction
13%
T Cell
41%
Tissue Distribution
10%
Transplant Procedure
21%
Tree
10%
Vasculotropin C
10%
Pharmacology, Toxicology and Pharmaceutical Science
Alemtuzumab
10%
Alisertib
12%
Anthracycline
26%
Avelumab
10%
Azacitidine
10%
Biological Marker
13%
Bleomycin
29%
Cardiotoxicity
15%
Chemotherapy
41%
Classical Hodgkin Lymphoma
34%
Cohort Study
21%
Comorbidity
10%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Diffuse Large B Cell Lymphoma
50%
Disease
14%
Doxorubicin
11%
Epstein-Barr Virus
18%
Etoposide
16%
Follicular Lymphoma
9%
Galectin 1
10%
Growth Promotor
10%
Hodgkin Disease
34%
Ibritumomab Tiuxetan
19%
Idiopathic Thrombocytopenic Purpura
10%
Immunotherapy
11%
Isoniazid
10%
Lung Toxicity
21%
Lymphoma
13%
Mantle Cell Lymphoma
10%
Molecular Epidemiology
10%
Monotherapy
21%
Neoplasm
12%
Nonhodgkin Lymphoma
13%
Overall Survival
35%
Paraneoplastic Pemphigus
10%
Peripheral T Cell Lymphoma
32%
Pixantrone
21%
Posttransplant Lymphoproliferative Disease
10%
Programmed Cell Death
10%
Programmed Death 1 Receptor
13%
Progression Free Survival
36%
Randomized Clinical Trial
10%
Remission
20%
Rituximab
42%
Styrene
10%
Survival Rate
10%
T Cell Lymphoma
13%
Virus DNA
10%
Yttrium 90
10%
Zanolimumab
10%